Clinical Trials

150 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT06830720 2026-04-01

CAROLEEN

Recruiting

3,250 enrolled

Breast Neoplasms

NCT04791384 2026-03-31

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Phase 1/2 Terminated

5 enrolled

Breast Neoplasms

NCT05307705 2026-03-27

PIKASSO-01

193 enrolled

Breast Neoplasms

NCT07487129 2026-03-23

Clinical and P

Phase 4 Completed

206 enrolled

Breast Neoplasms

NCT05573126 2026-03-20

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

95 enrolled

Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Breast Neoplasms

NCT07100106 2026-03-12

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

285 enrolled

Breast Neoplasms

NCT05524584 2026-03-11

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Phase 2 Recruiting

20 enrolled

Breast Neoplasms

NCT05708235 2026-03-05

MiRaDoR

Phase 2 Recruiting

976 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms, Neoplasm, Residual

NCT07428018 2026-03-05

VIOLET

150 enrolled

Breast Neoplasms

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

1,020 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT03130439 2026-02-20

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

Phase 2 Terminated

27 enrolled 17 charts

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07410559 2026-02-18

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

189 enrolled

Breast Neoplasms

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast Neoplasms

NCT06678269 2026-02-12

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Phase 1 Recruiting

28 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT05548127 2026-02-10

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

37 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT02747004 2026-02-06

Next MONARCH 1

234 enrolled 20 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT02763566 2026-02-05

MONARCH plus

463 enrolled 20 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT02246621 2026-02-03

MONARCH 3

493 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT03616587 2026-01-28

SERENA-1

396 enrolled

Breast Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

198 enrolled

Breast Neoplasms

NCT02779751 2026-01-26

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer